Hydroxyapatite filler and preparation method thereof
Through the grafting treatment of hydroxyapatite and oligomeric hyaluronic acid, the problems of dispersion and poor fibroblast affinity of hydroxyapatite in the field of facial filling are solved, and filling with excellent mechanical and biological properties is formed The agent significantly improves its effect and safety on the face.
Patent Information
- Application Number
- CN202411141399.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
AI Technical Summary
In the prior art, gel products prepared by mixing hydroxyapatite with natural polymer materials have problems such as poor dispersion, easy displacement and poor fibroblast affinity, resulting in poor application effect in the field of facial filling.
By dispersing hydroxyapatite in a mixed solution of ethanol and water, and treating it with oligomeric hyaluronic acid, adjusting the pH to 4.5-6.5, adding accelerator and mixing, it can be achieved through centrifugation, redissolution and stirring, etc. The grafting of oligomer hyaluronic acid and hydroxyapatite improves its compatibility and stability, and forms a modified hydroxyapatite filler.
The modified hydroxyapatite filler is evenly dispersed in normal saline, has good mechanical and biological properties, reduces sedimentation, promotes collagen regeneration, improves facial filling effect, and is safe and suitable for Medical beauty field.
Smart Images

Figure CN119015493A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of implantable biomedical materials, and more specifically relates to a hydroxyapatite filler and a preparation method thereof. Background Art
[0002] Facial aging is ultimately due to calcium loss (i.e., decreased bone density) and collagen loss. Currently, hydroxyapatite has mechanical support and a certain structural strength, which can highly simulate the support effect of bones, supplement the missing bone position, and its regeneration mechanism can stimulate collagen regeneration. Therefore, hydroxyapatite can be used as a raw material for in vivo implantation in the fields of plastic surgery and skin care. Through the role of hydroxyapatite, the new collagen can supplement the collagen lost in the skin, thereby improving the problem of looseness, sagging or sunken.
[0003] Hydroxyapatite (Ca 10 (PO4)6(OH)2) is mainly composed of calcium, phosphorus and other elements. When hydroxyapatite is used alone, it is easy to have disadvantages such as poor support effect, high brittleness and rapid precipitation in physiological saline. Therefore, hydroxyapatite is currently mixed with natural polymer components such as collagen or hyaluronic acid (facial filling materials) to form gel products to meet clinical needs. For example, the Chinese patent with publication number CN117582549A discloses an injectable recombinant collagen soft tissue filling gel including recombinant collagen solution, sodium hyaluronate solution for injection, medicinal glycerin and medical hydroxyapatite.
[0004] However, the gel products prepared by mixing natural polymer materials with hydroxyapatite still have the disadvantages of poor hydroxyapatite dispersion and easy displacement. Moreover, when the gel products mixed with natural polymer materials and hydroxyapatite are implanted in the body, since natural polymer materials such as recombinant collagen and hyaluronic acid have poor affinity for fibroblasts, it is necessary to wait for the natural polymer materials to degrade or metabolize in the body (generally 8-24 weeks) before fibroblasts can adhere, spread, proliferate and aggregate on the surface of hydroxyapatite, stimulating regeneration and forming a large amount of extracellular matrix. It can be seen that the application of hydroxyapatite in the field of facial filling still needs to be further improved. Summary of the invention
[0005] In view of the above-mentioned defects and problems of the prior art, the present invention develops a hydroxyapatite filler and a preparation method thereof.
[0006] The first aspect of the present invention provides a method for preparing a hydroxyapatite filler, comprising the following steps:
[0007] (1) dispersing hydroxyapatite in a mixed solution of ethanol and water, and adjusting the pH to 4.5-6.5 to obtain a hydroxyapatite solution;
[0008] (2) dissolving oligomeric hyaluronic acid in water, adding 1-ethyl-3-(3-dimethylamino)propyl-carbodiimide (EDC), and adjusting the pH to 4.5-6.5 to obtain an oligomeric hyaluronic acid solution;
[0009] (3) mixing the hydroxyapatite solution and the oligomeric hyaluronic acid solution in a mass ratio of 1:1 to 3:1, adding an accelerator, and stirring to obtain a modified hydroxyapatite solution;
[0010] (4) centrifuging the modified hydroxyapatite solution, removing the supernatant to obtain a first precipitate, washing the first precipitate, dispersing the washed first precipitate in a mixed solution of ethanol and water, adding oligomeric hyaluronic acid to form a first solution, adjusting the pH of the first solution to 5.6-7.2, stirring at 10-40° C. for a first time, and then stirring at 2-8° C. for a second time to obtain a second solution;
[0011] (5) centrifuging the second solution, removing the supernatant to obtain a second precipitate, redissolving the second precipitate in water, shaking, centrifuging again and obtaining a third precipitate, and after the third precipitate is subjected to a post-processing step, obtaining the hydroxyapatite filler.
[0012] In the present invention, "oligomeric hyaluronic acid" is defined as a hyaluronic acid with a molecular weight of less than 10000Da. Preferably, the oligomeric hyaluronic acid is a hyaluronic acid with a molecular weight range of 100Da to 5000Da. More preferably, the oligomeric hyaluronic acid is a hyaluronic acid with a molecular weight range of 500Da to 3000Da. Most preferably, the oligomeric hyaluronic acid is a hyaluronic acid with a molecular weight range of 1000Da to 2000Da. Studies have shown that oligomeric hyaluronic acid has multiple biological activities such as anti-oxidation, promoting bone and angiogenesis, promoting wound healing, and immunomodulation.
[0013] The inventors unexpectedly discovered that by treating oligomeric hyaluronic acid and hydroxyapatite separately and then mixing them in a suitable ratio under the action of a promoter, the oligomeric hyaluronic acid can be effectively grafted onto the hydroxyapatite. Then, through the treatment of step (4), the stability of the grafted oligomeric hyaluronic acid-hydroxyapatite can be promoted by enhancing the firmness of the network between the oligomeric hyaluronic acid and the hydroxyapatite, so that the finally prepared hydroxyapatite filler will not have poor performance due to the easy sedimentation of hydroxyapatite, and the oligomeric hyaluronic acid injected into the body will not be easily displaced and degraded too quickly due to the grafting with the hydroxyapatite, thereby promoting the entire hydroxyapatite filler to play a better role, and the effect is better than the product of a mixture of high molecular weight hyaluronic acid and hydroxyapatite. It should be noted that although oligomeric hyaluronic acid is added in step (4), no other chemical reagents that promote the grafting reaction are added, and the oligomeric hyaluronic acid in this step does not actually participate in the grafting reaction. Therefore, this step does not require washing, and the free oligomeric hyaluronic acid can be directly removed by re-dissolving and centrifuging.
[0014] Through the coordination between the above steps, the purpose of grafting oligomeric hyaluronic acid on hydroxyapatite is achieved, the compatibility between hydroxyapatite and oligomeric hyaluronic acid is improved, the dispersibility of hydroxyapatite is improved, and the hydroxyapatite filler is promoted to exert excellent mechanical and biological properties. The prepared hydroxyapatite filler is not easy to settle and has a suitable pushing force, which can be better used in the field of medical beauty filling. When the hydroxyapatite filler takes effect, the surface-grafted oligomeric hyaluronic acid can degrade relatively quickly (compared to polymer materials with larger molecular weight) while nourishing the skin, exposing the hydroxyapatite, allowing the hydroxyapatite to stay at the filling site, stimulating the in situ regeneration of collagen at the filling site, promoting the thickening of the dermis, and allowing the filled site to be replaced by new autologous tissue, achieving the purpose of filling the sunken parts of the face, and has a relatively broad application prospect.
[0015] During the above preparation process, no other additives are introduced, and the promoters used will not appear in the final product. Therefore, the grafted hydroxyapatite is relatively safe and can be well used in the field of medical beauty filling.
[0016] Optionally, the promoter includes at least one of N-hydroxy-succinic acid amide (NHS), 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (DMTMM) and hydroxybenzotriazole N-hydroxy-succinic acid amide (HOBt); preferably, the molar ratio of the promoter to the 1-ethyl-3-3-dimethylaminopropyl-carbodiimide is 0.2:5 to 2:5.
[0017] Optionally, in step (1) and step (2), 2-morpholineethanesulfonic acid (MES) is used to adjust the pH.
[0018] Optionally, in step (4), the mass ratio of the oligomeric hyaluronic acid to the first precipitate is 1:8 to 1:15.
[0019] Optionally, in step (4), the first time is 1-3 hours; the second time is 8-16 hours.
[0020] It should be noted that stirring at 10-40°C for 1-3 hours can help the calcium ions in the grafted oligomeric hyaluronic acid-hydroxyapatite to be micro-ionized, strengthen the coordination network between calcium ions and oligomeric hyaluronic acid, and promote the grafting stability between oligomeric hyaluronic acid and hydroxyapatite. Then, stirring in a low-temperature environment for 8-16 hours can promote the hydrogen bonding force in the grafted oligomeric hyaluronic acid-hydroxyapatite, further allowing the grafted oligomeric hyaluronic acid-hydroxyapatite to maintain the grafted state for a long time, and thus allowing the prepared hydroxyapatite filler to continue to exert excellent facial filling performance.
[0021] Optionally, the preparation method satisfies at least one of the following conditions (a) to (e):
[0022] (a) In step (1), the particle size of the hydroxyapatite is 20-60 μm;
[0023] (b) In step (1), the mass fraction of hydroxyapatite in the hydroxyapatite solution is 4%-20%;
[0024] (c) In step (2), in the oligomeric hyaluronic acid solution, the mass fraction of the oligomeric hyaluronic acid is 2%-10%, and the mass fraction of the 1-ethyl-3-3-dimethylaminopropyl-carbodiimide is 2-6%;
[0025] (d) In step (3), adding a promoter at a temperature of 20-60° C. and stirring for 10-60 min;
[0026] (e) In step (1) and step (4), the volume ratio of ethanol to water in the mixed solution of ethanol and water is 1:1 to 9:1.
[0027] Optionally, in step (5), the post-processing step includes drying, grinding, sieving, freeze-drying and sterilization; preferably, the third precipitate is dried at a temperature of 50-80° C. for 4-10 h.
[0028] Optionally, in step (5), an excipient is added to the sieved third precipitate and then freeze-dried; preferably, the excipient is selected from one or more of mannitol, trehalose and sorbitol.
[0029] Optionally, in the hydroxyapatite filler, the grafting rate of hydroxyapatite is 11.8%-15.7%.
[0030] Another aspect of the present invention further provides the above-mentioned hydroxyapatite filler, which is prepared by the preparation method of the first aspect.
[0031] In summary, the present invention has the following beneficial effects:
[0032] Through the coordination between each step, oligomeric hyaluronic acid is grafted on hydroxyapatite, which improves the compatibility between hydroxyapatite and oligomeric hyaluronic acid, improves the dispersibility of hydroxyapatite, and makes the hydroxyapatite filler not easy to settle and the pushing force is appropriate; the preparation method and reaction conditions of the present invention can not only greatly improve the grafting efficiency of oligomeric hyaluronic acid on hydroxyapatite, but also enhance the coordination and complexation between the carboxyl group in oligomeric hyaluronic acid and the calcium ion of hydroxyapatite calcium, and the hydrogen bonding between oligomeric hyaluronic acid and hydroxyl group of hydroxyapatite calcium, thereby forming a chemical grafting-physical cross-linking double network dual effect. The modified hydroxyapatite can be evenly dispersed in physiological saline, has good performance advantages, and can be directly used as freeze-dried powder. In the preparation process, no other additives are introduced, and the accelerators used will not appear in the final product. Therefore, the grafted hydroxyapatite is safer and can be better applied in the field of medical beauty filling, and has a wider application prospect. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.
[0034] Figure 1 The infrared spectra of the sample powder of Example 1 and the untreated natural hydroxyapatite sample powder;
[0035] Figure 2 It is a comparison diagram of the appearance of the samples of Example 1 and Comparative Example 1, the untreated hydroxyapatite solution and the samples of the direct mixing group. DETAILED DESCRIPTION
[0036] The present invention is further described below in conjunction with examples. It should be understood that the examples are only used to further illustrate and explain the present invention, and are not intended to limit the present invention.
[0037] Unless otherwise defined, the technical terms and scientific terms in this specification have the same meaning as those commonly understood by those skilled in the art. Although similar or identical methods and materials as those described herein may be used in experiments or practical applications, the materials and methods are described herein below. In the event of a conflict, the present specification including the definitions therein shall prevail. In addition, the materials, methods and examples are provided for illustration only and are not intended to be limiting.
[0038] The test methods, detection methods and conventional experimental reagent preparation methods used in the embodiments of the present invention are all in accordance with conventional operations in the art unless otherwise specified.
[0039] In order to facilitate the description of the technical solution of the present invention, the following materials and steps are described before starting the experiment of the present invention:
[0040] The sources of the main raw materials in the present invention are as follows:
[0041] Hydroxyapatite: purchased from Shaanxi Bioa Regenerative Medicine Co., Ltd., CAS number 1306-06-5;
[0042] Oligomeric hyaluronic acid: purchased from Shandong Zhongshan Biotechnology Co., Ltd., CAS number is 9004-61-9.
[0043] Example 1
[0044] The preparation method of hydroxyapatite filler is as follows:
[0045] (1) Natural hydroxyapatite with a particle size of 20-60 μm is dispersed in a mixed solution of ethanol and deionized water, wherein the ratio of ethanol to deionized water is 1:1, and the pH of the solution is adjusted to 5 using MES to prepare a hydroxyapatite solution with a mass fraction of 16%.
[0046] (2) Dissolve oligomeric hyaluronic acid with a molecular weight of 1000-2000Da in deionized water, add EDC, adjust the pH of the solution to 5 using MES, stir at 25°C for 15 minutes, and prepare an oligomeric hyaluronic acid solution with a mass fraction of 6%, wherein the mass fraction of EDC in the oligomeric hyaluronic acid solution is 2%.
[0047] (3) The hydroxyapatite solution and the oligomeric hyaluronic acid solution were mixed in a mass ratio of 1:1, and NHS was added at a temperature of 25° C., with the molar ratio of EDC to NHS being 5:1. The mixture was stirred for 12 h to obtain a modified hydroxyapatite solution.
[0048] (4) Centrifuging the modified hydroxyapatite solution, removing the supernatant to obtain a first precipitate, backwashing the first precipitate with ethanol and deionized water for 8 times to remove the crosslinker and the promoter, dispersing the washed first precipitate in a mixed solution of ethanol and deionized water in a volume ratio of 4:1, and adding oligomeric hyaluronic acid with a molecular weight of 1000-2000Da to form a first solution, wherein the mass ratio of the oligomeric hyaluronic acid to the first precipitate is 1:10, adjusting the pH of the first solution to 6.0 using hydrochloric acid and phosphate buffer, stirring at 25°C for 1 hour, and then stirring at 4°C for 10 hours to form a second solution.
[0049] (5) The second solution was centrifuged, and the supernatant was removed to obtain a second precipitate, which was redissolved in deionized water, vortexed for 5 minutes, and centrifuged again to obtain a third precipitate. The third precipitate was dried in an oven at 60° C. for 6 hours, ground, sieved, and 80 mg of mannitol was added to mix evenly, and then freeze-dried and sterilized to obtain a hydroxyapatite filler.
[0050] Example 2
[0051] The preparation method of hydroxyapatite filler is as follows:
[0052] The difference from Example 1 is that NHS is replaced with the same amount of HOBt.
[0053] Example 3
[0054] The preparation method of hydroxyapatite filler is as follows:
[0055] The difference from Example 1 is that NHS is replaced by the same amount of DMTMM.
[0056] Example 4
[0057] The preparation method of hydroxyapatite filler is as follows:
[0058] The difference from Example 1 is that in step (1), natural hydroxyapatite with a particle size of 20-60 μm is dispersed in a mixed solution of ethanol and deionized water in a volume ratio of 4:1; in step (4), the first precipitate is dispersed in a mixed solution of ethanol and deionized water in a volume ratio of 1:1.
[0059] Comparative Example 1
[0060] The sample preparation method is as follows:
[0061] The difference from Example 1 is that the oligomeric hyaluronic acid is replaced with hyaluronic acid with a molecular weight of 200,000-400,000 Da.
[0062] Comparative Example 2
[0063] The sample preparation method is as follows:
[0064] The difference from Example 1 is that the pH is not adjusted in step (1).
[0065] Comparative Example 3
[0066] The sample preparation method is as follows:
[0067] The difference from Example 1 is that the pH is not adjusted in step (2).
[0068] Comparative Example 4
[0069] The sample preparation method is as follows:
[0070] The difference from Example 1 is that NHS is not added in step (3).
[0071] Comparative Example 5
[0072] The sample preparation method is as follows:
[0073] The difference from Example 1 is that in step (3), the mass ratio of the hydroxyapatite solution to the oligomeric hyaluronic acid solution is 1:3.
[0074] Comparative Example 6
[0075] The sample preparation method is as follows:
[0076] The difference from Example 1 is that in step (3), the mass ratio of the hydroxyapatite solution to the oligomeric hyaluronic acid solution is 4:1.
[0077] Comparative Example 7
[0078] The sample preparation method is as follows:
[0079] The difference from Example 1 is that step (4) is not performed, and in step (5), the modified hydroxyapatite solution is centrifuged, the supernatant is removed to obtain a first precipitate, the first precipitate is repeatedly washed with ethanol and deionized water for 8 times, the first precipitate is dried in an oven at 60°C for 6 h, ground, sieved, 80 mg of mannitol is added to mix evenly, freeze-dried and sterilized.
[0080] Comparative Example 8
[0081] The sample preparation method is as follows:
[0082] The difference from Example 1 is that step (4) is only stirred at 25° C. for 11 h to form a second solution.
[0083] Comparative Example 9
[0084] The sample preparation method is as follows:
[0085] The difference from Example 1 is that step (4) is only stirred at 4° C. for 11 h to form a second solution.
[0086] Performance testing
[0087] Performance test 1 Grafting rate calculation
[0088] Test method: Take 0.1g of the samples prepared in Examples 1-4 and Comparative Examples 1-9 respectively, and re-dissolve them with physiological saline to prepare a 20mg / ml test sample solution, vortex and shake to mix evenly, and fill it into a prefilled syringe. According to the method in Appendix C: Sodium Hyaluronate Content of YY / T 0962-2021 "Cross-linked Sodium Hyaluronate Gel for Plastic Surgery", the hyaluronic acid content in the above-mentioned test sample solution is calculated, and the ratio of the hyaluronic acid content in the test sample solution to the total content of the test sample is used to calculate the grafting rate of hyaluronic acid. The data of the grafting rate are shown in Table 1.
[0089] Table 1. Grafting rate of samples obtained from Examples 1-4 and Comparative Examples 1-9
[0090]
[0091] It can be seen from the data in Table 1 that a hydroxyapatite filler with a certain grafting rate can be prepared by the preparation method of the present invention, while in Comparative Example 1, due to the large molecular weight of hyaluronic acid, the self-crosslinking degree of hyaluronic acid is high, and it may be based on steric hindrance and coating effects. 200,000-400,000 Da hyaluronic acid and hydroxyapatite cannot be effectively grafted. By comparing the data of Comparative Example 2, Comparative Example 3 and Example 1, it can be seen that not adjusting the pH in step (1) and step (2) also seriously affects the grafting rate of hydroxyapatite; according to the data of Comparative Example 4, when NHS is not added in step (3), the grafting rate of hydroxyapatite is only 1.52%. It can be seen from Comparative Examples 5 and 6 that the strict control of the mass ratio of hydroxyapatite solution and oligomeric hyaluronic acid solution is also very important. When the amount of hydroxyapatite solution or oligomeric hyaluronic acid solution added is not appropriate, the grafting rate of hydroxyapatite solution is also low. According to the data of Comparative Examples 7 to 9, it can be seen that it is very important to carry out step (4), and the process parameters in step (4) also have a great influence on the grafting efficiency of hydroxyapatite.
[0092] In addition, taking Example 1 as an example, the sample powder of Example 1 and the untreated natural hydroxyapatite sample powder (referred to as the untreated sample) were respectively taken, and the samples before and after grafting were analyzed by infrared spectroscopy. The test results are as follows: Figure 1 shown.
[0093] By analyzing Figure 1 It can be seen that the method provided by the present invention can make hydroxyapatite after grafting, 3500cm -1 The hydroxyl peaks around 1600 and 1400 cm -1 Characteristic absorption peaks of hyaluronic acid appear on the left and right, indicating that oligomeric hyaluronic acid can be successfully grafted onto hydroxyapatite through the preparation method of the present invention.
[0094] Performance test 2: Sample sedimentation time test
[0095] Test method: Take 0.1g of the samples prepared in the above-mentioned Examples 1-4 and Comparative Examples 1-9 respectively, use the same volume of physiological saline to reconstitute, and vortex to mix evenly. Let it stand and observe at different times, record the stratification of each sample at different time points, and set 4 levels according to the stratification (0 level represents no stratification, 1 level represents slight stratification, 2 level represents partial stratification, and 3 level represents complete stratification). The sedimentation time results of the samples of Examples 1-4 and Comparative Examples 1-9 are shown in Table 2.
[0096] Table 2. Sample sedimentation time results of Examples 1-4 and Comparative Examples 1-9
[0097]
[0098] According to the data in Table 2, the preparation method provided by the present invention can help improve the dispersibility of hydroxyapatite by grafting oligomeric hyaluronic acid onto hydroxyapatite, significantly improve the sedimentation performance of hydroxyapatite in physiological saline, thereby effectively improving the stability and application range of hydroxyapatite fillers. The gel product prepared in Comparative Example 1 also showed slight stratification after being placed for 1 hour, which may be due to slight sedimentation of hydroxyapatite wrapped in high molecular weight hyaluronic acid. The samples prepared in Comparative Examples 2-9, due to the large amount of free hydroxyapatite, precipitated faster and the solution stratification phenomenon was serious.
[0099] The appearance state diagram of the sample of Example 1 and the sample of Comparative Example 1 at 1 hour, the appearance state diagram of the untreated equal amount of natural hydroxyapatite sample powder solution (referred to as untreated sample) and the direct mixed group sample after being placed for 10 minutes are as follows: Figure 2 The preparation method of the direct mixing group samples is as follows:
[0100] (1) Natural hydroxyapatite with a particle size of 20-60 μm is dispersed in a mixed solution of ethanol and deionized water, wherein the ratio of ethanol to deionized water is 1:1, to prepare a hydroxyapatite solution with a mass fraction of 16%.
[0101] (2) Dissolve oligomeric hyaluronic acid with a molecular weight of 1000-2000 Da in deionized water to prepare an oligomeric hyaluronic acid solution with a mass fraction of 6%.
[0102] (3) The hydroxyapatite solution and the oligomeric hyaluronic acid solution were mixed in a mass ratio of 1:1 to obtain a direct mixing group sample solution.
[0103] Depend on Figure 2 It can be seen that if oligomeric hyaluronic acid is simply mixed with hydroxyapatite, the hydroxyapatite will settle quickly, resulting in obvious stratification of the entire sample solution, and it cannot be used for normal skin implant applications.
[0104] Performance test 3 sample pushing force test
[0105] Test method: Take 0.1g of the samples prepared in Examples 1-4 and Comparative Examples 1-9 above, respectively, reconstitute with physiological saline, vortex and oscillate to mix evenly, and fill into a prefilled syringe. The sample pushing force is tested in accordance with Appendix A of YY / T0962-2021 "Cross-linked Sodium Hyaluronate Gel for Plastic Surgery": Determination of the Pushing Force of the Syringe Core Rod. During the experiment, a 32G injection needle was installed to simulate actual use. The core rod was pushed at a constant speed, and the sample in the syringe was pushed out through the needle to obtain the pushing force data, as shown in Table 3.
[0106] Table 3. Pushing force of samples obtained from Examples 1-4 and Comparative Examples 1-9
[0107]
[0108]
[0109] It can be seen from the above data that the samples prepared in Examples 1-4 do not affect the difficulty of injection when used, while in Comparative Examples 2-9, the sample precipitation may block the needle due to sedimentation. In Comparative Example 1, because hyaluronic acid with a larger molecular weight is used for grafting, the hyaluronic acid itself is cross-linked, the sample viscosity is larger, and the pushing force is also larger, which may cause needle bursting and affect the injection.
[0110] Performance test 4 sample cytotoxicity test
[0111] Test method: Referring to the standard "GB / T 16886.5-2017 Biological Evaluation of Medical Devices", according to the contact mode between materials and cells, the MTT test method was used in this experiment to test the cytotoxicity of the samples prepared in Examples 1-4, and rat fibroblasts were used for the experiment. The data were processed and the toxicity of the materials was evaluated according to Table 4. The relative proliferation rate data and cytotoxicity data of Examples 1-4 are shown in Table 5.
[0112] Table 4. Cytotoxicity grading criteria
[0113] Relative cell proliferation rate (%) Reaction classification Degree of reaction ≥100 Level 0 none 80-99 Level 1 slight 50-79 Level 2 Mild 30-49 Level 3 Moderate 0-29 Level 4 Severe
[0114] Table 5. Relative proliferation rate of cells in Examples 1-4
[0115] Experimental groups Example 1 Example 2 Example 3 Example 4 Average proliferation rate 95% 85% 100% 94% Cytotoxicity no no no no
[0116] From the data in Table 5, it can be seen that the samples prepared in Examples 1-4 are non-cytotoxic, which indicates that the preparation method proposed in the present invention will not affect the safety of the samples.
[0117] It should be understood that the disclosed invention is not limited only to the specific method, scheme and material of description, because these all can change.It should also be understood that the terminology used herein is only for the purpose of describing specific embodiment scheme, rather than being intended to limit the scope of the present invention, and the scope of the present invention is only limited to the appended claims.
[0118] Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are also intended to be encompassed by the appended claims.
Claims
1. A method for preparing a hydroxyapatite filler, characterized in that: The steps include: (1) dispersing hydroxyapatite in a mixed solution of ethanol and water, and adjusting the pH to 4.5-6.5 to obtain a hydroxyapatite solution; (2) dissolving oligomeric hyaluronic acid in water, adding 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, and adjusting the pH to 4.5-6.5 to obtain an oligomeric hyaluronic acid solution; (3) mixing the hydroxyapatite solution and the oligomeric hyaluronic acid solution in a mass ratio of 1:1 to 3:1, adding an accelerator, and stirring to obtain a modified hydroxyapatite solution; (4) centrifuging the modified hydroxyapatite solution, removing the supernatant to obtain a first precipitate, washing the first precipitate, dispersing the washed first precipitate in a mixed solution of ethanol and water, adding oligomeric hyaluronic acid to form a first solution, adjusting the pH of the first solution to 5.6-7.2, stirring at 10-40° C. for a first time, and then stirring at 2-8° C. for a second time to obtain a second solution; (5) centrifuging the second solution, removing the supernatant to obtain a second precipitate, redissolving the second precipitate in water, shaking, centrifuging again and obtaining a third precipitate, and after the third precipitate is subjected to a post-processing step, obtaining the hydroxyapatite filler.
2. The preparation method according to claim 1, characterized in that: The accelerator includes at least one of N-hydroxy-succinic acid amide, 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride and hydroxybenzotriazole N-hydroxy-succinic acid amide; preferably, the molar ratio of the accelerator to the 1-ethyl-3-3-dimethylaminopropyl-carbodiimide is 0.2:5 to 2:
5.
3. The preparation method according to claim 1, characterized in that: In step (1) and step (2), 2-morpholineethanesulfonic acid is used to adjust the pH.
4. The preparation method according to claim 1, characterized in that: In step (4), the mass ratio of the oligomeric hyaluronic acid to the first precipitate is 1:8 to 1:
15.
5. The preparation method according to claim 1, characterized in that: In step (4), the first time is 1-3 hours; the second time is 8-16 hours.
6. The preparation method according to claim 1, characterized in that: The preparation method satisfies at least one of the following conditions (a) to (e): (a) In step (1), the particle size of the hydroxyapatite is 20-60 μm; (b) In step (1), the mass fraction of hydroxyapatite in the hydroxyapatite solution is 4%-20%; (c) In step (2), in the oligomeric hyaluronic acid solution, the mass fraction of the oligomeric hyaluronic acid is 2%-10%, and the mass fraction of the 1-ethyl-3-3-dimethylaminopropyl-carbodiimide is 2-6%; (d) In step (3), adding a promoter at a temperature of 20-60° C. and stirring for 10-60 min; (e) In step (1) and step (4), the volume ratio of ethanol to water in the mixed solution of ethanol and water is 1:1 to 9:
1.
7. The preparation method according to claim 1, characterized in that: In step (5), the post-processing steps include drying, grinding, sieving, freeze-drying and sterilization; preferably, the third precipitate is dried at a temperature of 50-80° C. for 4-10 h.
8. The preparation method according to claim 7, characterized in that: In step (5), an excipient is added to the sieved third precipitate and then freeze-dried; preferably, the excipient is selected from one or more of mannitol, trehalose and sorbitol.
9. The preparation method according to any one of claims 1 to 8, characterized in that: In the hydroxyapatite filler, the grafting rate of hydroxyapatite is 11.8%-15.7%.
10. A hydroxyapatite filler, characterized in that: It is prepared by the preparation method described in any one of claims 1 to 9.
Citation Information
Cited By
Hydroxyapatite-based face filling material and preparation process thereof
CN121243471A
